A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 4, 2004, Pages 276-282

  Jones, Roy B ^a   Stockerl Goldstein, Keith E ^b   Klein, Jared ^c   Murphy, James ^d   Blume, Karl G ^b   Dansey, Roger ^c   Martinez, Charles ^a   Matthes, Steven ^a   Nieto, Yago ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Acute lung injury; Amifostine; BCNU; Hematopoietic cell transplantation

Indexed keywords

AMIFOSTINE; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOPAMINE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; INCIDENCE; LUNG INJURY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AMIFOSTINE; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PLACEBOS; RADIATION-PROTECTIVE AGENTS; RESPIRATORY DISTRESS SYNDROME, ADULT; TREATMENT OUTCOME;

EID: 1842426581     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.01.001     Document Type: Article

References (27)

1. Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies Semin Oncol. 23 4 suppl 8 1996 2-17
2. Kemp G. Rose P. Berman M. et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer J Clin Oncol. 14 1996 2101-2112
3. Buntzel J. Schuth J. Kuttner K. Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer Support Care Cancer 6 1998 155-160
4. Phillips G.L. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation Semin Oncol. 296 suppl 19 2002 53-56
5. Mollman J.E. Glover D.J. Hogan W.M. et al. Cisplatin neurotoxicity. Risk factors, prognosis, and protection by WR-2721 Cancer 61 1988 2192-2195
6. Tannehill S.P. Mehta M.P. Larson M. et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial J Clin Oncol. 15 1997 2850-2857
7. Capizzi R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine Semin Oncol. 26 2 suppl 7 1999 3-21
8. Capizzi R.L. Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials Int J Hematol. 72 2000 425-435
9. Cao T.M. Negrin R.S. Stockerl-Goldstein K. et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation Biol Blood Marrow Transplant. 6 2000 387-394
10. Jones R.B. Matthes S. Shpall E.J. et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine J Natl Cancer Inst. 85 1993 640-647
11. Wilczynski S.W. Erasmus J.J. Petros W.P. Vredenburgh J.J. Folz R.J. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer Am J Respir Crit Care Med. 157 1998 565-573
12. Chap L. Shpiner R. Levine M. Norton L. Lill M. Glaspy J. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment Bone Marrow Transplant. 20 1997 1063-1067
13. Rubio C. Hill M.E. Milan S. O'Brien M.E. Cunningham D. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease Br J Cancer 75 1997 1044-1048
14. Peters W.P. Shpall E.J. Jones R.B. et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol. 6 1988 1368-1376
15. Jones R.B. Matthes S. Shpall E.J. et al. BCNU pharmacokinetics in 72 patients treated with high-dose combination chemotherapy and autologous bone marrow support. Analytical methodology and patient data J Chromatogr Biomed. 1994
16. Peters W.P. Rosner G. Vredenburgh J. et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 Proc Am Soc Clin Oncol. 18 1999 1a [meeting abstract]
17. Zander A.R. Culbert S. Jagannath S. et al. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia Cancer 59 1987 1083-1096
18. Chopra R. McMillan A.K. Linch D.C. et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients Blood 81 1993 1137-1145
19. Alberts D.S. Speicher L.A. Krutzsch M. et al. WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells Eur J Cancer 32A suppl 4 1996 S17-S20
20. Wasserman T.H. Phillips T.L. Ross G. Kane L. Differential protection against chemotherapeutic effects on bone marrow CFUs by WR-2721 Cancer Clin Trials 4 1981 3-6
21. Becker K. Schirmer R.H. 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems Methods Enzymol. 251 1995 173-188
22. Davis M.R. Kassahun K. Jochheim C.M. Brandt K.M. Baillie T.A. Glutathione and N-acetylcysteine conjugates of 2-chloroethyl isocyanate. Identification as metabolites of N,N′-bis(2-chloroethyl)-N-nitrosourea in the rat and inhibitory properties toward glutathione reductase in vitro Chem Res Toxicol. 6 1993 376-383
23. Sriramachari S. Jeevaratnam K. Comparative toxicity of methyl isocyanate and its hydrolytic derivatives in rats Arch Toxicol. 69 1994 45-51
24. Durant J.R. Norgard N.J. Murad T.M. Bartolucci A.A. Langford K.H. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU) Ann Intern Med. 90 1979 191-194
25. Seiden M.V. Elias A. Ayash L. et al. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens Bone Marrow Transplant. 10 1992 57-63
26. Todd N.W. Peters W.P. Ost A.H. Roggli V.L. Piantadosi C.A. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation Am Rev Respir Dis. 147 1993 1264-1270
27. Jones R.B. Matthes S. Shpall E.J. et al. Acute lung injury following high-dose cyclophosphamide, cisplatin and BCNU. Pharmacodynamic evaluation of BCNU J Natl Cancer Inst. 85 1993 640-647